SOGA3: A Potential Drug Target and Biomarker (G387104)

Target Name: SOGA3

NCBI ID: G387104

SOGA3

SOGA3: A Potential Drug Target and Biomarker

SOGA3 (secretory osteoporosis-associated protein-3) is a protein that is expressed in osteoporotic bones and has been linked to the development and progression of osteoporosis. SOGA3 has been shown to play a crucial role in regulating bone loss and is a potential drug target for the treatment of osteoporosis.

The protein SOGA3 is a member of the SOGA family, which is known for its role in the regulation of protein synthesis and degradation. SOGA3 is produced from a unique isoform, SOGA3-ISO2, which has distinct advantages over other isoforms. SOGA3-ISO2 has a longer half-life and is expressed at higher levels than other isoforms. These properties make SOGA3-ISO2 an attractive target for drug development due to its potential to minimize the risk of adverse side effects associated with long-lived proteins.

SOGA3 has been shown to promote bone loss and is a key player in the development of osteoporosis. SOGA3 has been shown to stimulate the production of matrix-inhibiting cytokines, such as PTHrR1, which can lead to the activation and proliferation of osteoclasts, the cells responsible for breaking down bone tissue. Additionally, SOGA3 has been shown to inhibit the activity of bone-specific osteoprotective cytokines, such as RANKL, which can further contribute to bone loss.

SOGA3 has also been shown to be involved in the regulation of bone density and bone geometry. SOGA3 has been shown to play a role in the regulation of bone size and shape, as well as the maintenance of bone mass. SOGA3 has been shown to stimulate the production of bone-specific cytokines, such as FGF-1, which can contribute to bone growth and density.

Due to its role in the regulation of bone loss and growth, SOGA3 has been identified as a potential drug target for the treatment of osteoporosis. SOGA3 has been shown to be involved in the regulation of many cellular processes that are important for bone health, including cell signaling, protein synthesis, and cytokine regulation.

In conclusion, SOGA3 is a protein that has been shown to play a crucial role in the development and progression of osteoporosis. SOGA3 has been shown to promote bone loss, stimulate the production of matrix-inhibiting cytokines, and inhibit the activity of bone-specific osteoprotective cytokines. As a result, SOGA3 is a potential drug target for the treatment of osteoporosis. Further research is needed to fully understand the role of SOGA3 in osteoporosis and to develop effective treatments.

Protein Name: SOGA Family Member 3

The "SOGA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOGA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets